Vivani Medical, Inc. · NASDAQ:VANI
Vivani Medical — Second Sight Medical Products — Investor Presentation (May 2018)
12 slides from Vivani Medical's investor presentation, May 24, 2018
Slide 1: Enriching the Lives of the Blind
NASDAQ: EYES Enriching the Lives of the Blind May 2018 NASDAQ: EYES
Slide 2: Forward Looking Statements
NASDAQ: EYES Forward Looking Statements This press release contains forward - looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange and Exchange Act of 1934, as amended, which are intended to be covered by the "safe
Slide 3: Two Breakthrough Technologies
NASDAQ: EYES Two Breakthrough Technologies Argus® II retinal prosthesis 3 Glasses and Video Processing Unit Electronics Case Electrode Array Receiver (coil) Electrode array implant on surface of brain Video Camera in Glasses Wireless Transmitter Orion ™ I visual cortical prosthesis system • First an
Slide 4: Argus II: Effective Treatment for Blindness
NASDAQ: EYES Argus® II: Effective Treatment for Blindness Argus II is a retinal prosthesis that induces visual perception in individuals with severe to profound retinitis pigmentosa (RP) 4
Slide 5: Orion I: Breakthrough Device
NASDAQ: EYES Orion I: Breakthrough Device Leveraging Argus II technology, our breakthrough Orion platform bypasses the damaged eye and/or optic nerve to directly stimulate the brain • Orion has the potential to treat many forms of blindness including glaucoma, diabetic retinopathy, forms of cancer a
Slide 6: Poised for Growth
NASDAQ: EYES Poised for Growth 20 years Technology innovation 5+ years Commercial execution + Argus II Argus II Expanded Indications Orion I • 276+ implants • 14 markets worldwide • Large patient database • Approved reimbursement in multiple markets Foundation for growth = • 2018: Submitted HDE supp
Slide 7: Commercial Experience and Leverage
NASDAQ: EYES Commercial Experience and Leverage Established technology with 10 years+ experience implant durability Proprietary algorithms for artificial vision, leverage into Orion Argus II technology platform Established and growing new ophthalmology therapy in 14 markets worldwide, including the
Slide 8: Identifying and Recruiting Qualified Patients
NASDAQ: EYES Identifying and Recruiting Qualified Patients Broad media campaigns Locating qualified candidates for Argus II Most experienced Argus clinician coordinators Candidates are interviewed with standard questionnaire Scheduling with sites Steadily increasing volume and demand Patient Outreac
Slide 9: 2018 Key Drivers of Shareholder Value
NASDAQ: EYES Orion Argus II Orion Path to Commercializatio n Argus II Commercial 2018 Key Drivers of Shareholder Value Orion Feasibility Study Pivotal and post - market trial design via the FDA’s Breakthrough Device Program. Addressable market opportunity evaluated by 3 rd party Complete Orion feasi
Slide 10: Select Financial Data
NASDAQ: EYES Select Financial Data 10 1) Non - GAAP adjusted net loss excludes non - cash expenses including stock - based compensation and reserve for excess inventory. (USD $ in thousands) Q1 2018 FY 2017 FY 2016 Implants 16 75 (30 in Q4) 42 (7 in Q4) Revenue $976 $7,964 $3,985 Gross Profit (Loss)
Slide 11: Second Sight Investment Highlights
NASDAQ: EYES Second Sight Investment Highlights • Technology Innovator with two platforms Argus II retinal prosthesis • First and only FDA approved retinal prosthesis; 5+ year first mover advantage in the U.S. • 20 years and ~$200 million invested in established technology Orion I visual cortical pr
Slide 12: Contacts
NASDAQ: EYES Contacts Retail Investor Relations Greg Falesnik Managing Director MZ North America Direct: 949 - 385 - 6449 Greg.Falesnik@mzgroup.us 12 Second Sight Medical Products, Inc. 12744 San Fernando Road Suite 400 Sylmar, CA 91342 Main: 818 - 833 - 5000 www.secondsight.com Institutional Invest
Second Sight Medical Products — Investor Presentation (May 2018) on 6ix